Nelliebear

Posts · 40Posts · 40
Following · 0Following · 0
Followers · 0Followers · 0

- NelliebearNelliebear
  ·2023-03-16
  Keep the faith
  Needham Keeps Their Buy Rating on Esperion (ESPR)
  Needham analyst Serge Belanger maintained a Buy rating on Esperion (ESPR – Research Report) today an
  Needham Keeps Their Buy Rating on Esperion (ESPR)
  435 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-12-20
  💪
  Cosmos Health prices $32.5M direct offering
  Cosmos Health (NASDAQ:COSM) has entered into securities purchase agreements with institutional inves
  Cosmos Health prices $32.5M direct offering
  355 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-12-14
  👍
  Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy
  Nano cap biotech Harpoon Therapeutics (NASDAQ:HARP) added ~122% in the morning hours Monday after th
  Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy
  406 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-12-14
  👍
  Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial
  By Kathryn Hardison Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after
  Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial
  526 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-10-07
  👍
  There’s a ‘Battery’ of Reasons to Consider Investing in the Atlis Motor Vehicles IPO
  Atlis Motor Vehicles (AMV) recently had its initial public offering (IPO), and the share price veere
  There’s a ‘Battery’ of Reasons to Consider Investing in the Atlis Motor Vehicles IPO
  584 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-22
  Keep going 👍
  Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
  Bluebird Bio (BLUE) shares soared 15.7% in the last trading session to close at $6.86. The move was
  Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
  305 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-20
  Keep going 👍
  bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
  bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
  bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
  341 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-19
  Keep going 💪
  U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder
  Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's gene therapy for the
  U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder
  505 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-15
  Keep going 💪
  Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants
  Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Wa
  Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants
  500 Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-15
  💪 Keep going
  Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery
  Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever
  Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery
  231 Comment
  1
  Share
  Report

Most Discussed

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Nelliebear

Needham Keeps Their Buy Rating on Esperion (ESPR)

Cosmos Health prices $32.5M direct offering

Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy

Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial

There’s a ‘Battery’ of Reasons to Consider Investing in the Atlis Motor Vehicles IPO

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder

Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants

Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery

Most Discussed